Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1434994
This article is part of the Research Topic Tackling Breast, Brain, Lung and Ovarian Cancer with Nanomediated Delivery Systems: New Horizons in Cancer Treatment View all 5 articles

Nanomedicine in HNSCC therapy -A challenge to conventional therapy

Provisionally accepted
Chenyu Li Chenyu Li 1Yuan Fang Yuan Fang 2Sanchun Xu Sanchun Xu 1Jingyuan Zhao Jingyuan Zhao 3Deshi Dong Deshi Dong 2Shuai Li Shuai Li 2*
  • 1 Dalian Medical University, Dalian, Liaoning, China
  • 2 First Affiliated Hospital, Dalian Medical University, Dalian, China
  • 3 Affiliated Central Hospital of Dalian University of Technology, Dalian, Liaoning Province, China

The final, formatted version of the article will be published soon.

    Squamous cell carcinoma of the head and neck (HNSCC) is a difficult-to-treat cancer and treatment is challenging due to recurrence or metastasis. Therefore, there is an urgent need to explore more effective targeted therapies to improve the clinical outcomes and survival of HNSCC patients. The nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer therapy. In this review, we summarize some important signaling pathways and present the current and potential roles of various nanomaterial drug-delivery formulations in HNSCC treatment, aiming to understand the pathogenesis of HNSCC and further improve the therapeutic efficacy of nanomaterial HNSCC. This article seeks to highlight the exciting potential of novel nanomaterials for targeted cancer therapy in HNSCC and thus provide motivation for further research in this field.

    Keywords: head and neck cancer, molecular pathogenesis, Nano-drug, nanocarrier and delivery, Cancer

    Received: 19 May 2024; Accepted: 01 Oct 2024.

    Copyright: © 2024 Li, Fang, Xu, Zhao, Dong and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shuai Li, First Affiliated Hospital, Dalian Medical University, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.